BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:2051-2059. [PMID: 16848813 DOI: 10.1111/j.1572-0241.2006.00679.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Dong QZ, Zhang XF, Zhao Y, Jia HL, Zhou HJ, Dai C, Sun HJ, Qin Y, Zhang WD, Ren N. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology. 2013;57:1024-1034. [PMID: 23079960 DOI: 10.1002/hep.26103] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
2 Kulik LM. Advancements in hepatocellular carcinoma: . Current Opinion in Gastroenterology 2007;23:268-74. [DOI: 10.1097/mog.0b013e3280ec5113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Zhou C, Zhou HJ, Zhang XF, Lou LL, Ye QH, Zheng Y, Wang J, Zhu HT, Dong QZ, Jia HL, Zhu WW, Guo L, Zhao Y, Gao DM, Qin LX. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol 2013;20:929-37. [PMID: 23203407 DOI: 10.1245/s10434-012-2749-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
4 Simão A, Madaleno J, Silva N, Rodrigues F, Caseiro P, Costa JN, Carvalho A. Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. BMC Gastroenterol 2015;15:73. [PMID: 26122937 DOI: 10.1186/s12876-015-0307-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
5 Beckebaum S, Chen X, Sotiropoulos GC, Radtke A, Daoudaki M, Baba HA, Wohlschlaeger J, Broelsch CE, Gerken G, Cicinnati VR. Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection. Transplant Proc. 2008;40:3182-3184. [PMID: 19010227 DOI: 10.1016/j.transproceed.2008.08.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
6 Wu Y, Jiang W, Wang Y, Wu J, Saiyin H, Qiao X, Mei X, Guo B, Fang X, Zhang L, Lou H, Wu C, Qiao S. Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS One 2012;7:e42976. [PMID: 22927944 DOI: 10.1371/journal.pone.0042976] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
7 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 21.0] [Reference Citation Analysis]
8 Mehta A, Herrera H, Block T. Glycosylation and liver cancer. Adv Cancer Res. 2015;126:257-279. [PMID: 25727150 DOI: 10.1016/bs.acr.2014.11.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 10.5] [Reference Citation Analysis]
9 Fukuda T, Sanui T, Toyoda K, Tanaka U, Taketomi T, Uchiumi T, Nishimura F. Identification of novel amelogenin-binding proteins by proteomics analysis. PLoS One 2013;8:e78129. [PMID: 24167599 DOI: 10.1371/journal.pone.0078129] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
10 El-Khazragy N, Khalifa MM, Salem AM, Swellam M, Hegazy M. Evaluation of Osteopontin and Pokémon genes expression in hepatitis C virus-associated hepatocellular carcinoma. J Cell Biochem 2018. [PMID: 30417409 DOI: 10.1002/jcb.28018] [Reference Citation Analysis]
11 Zhou Y, Romson J, Emmer Å. An antibody-free sample pretreatment method for osteopontin combined with MALDI-TOF MS/MS analysis. PLoS One 2019;14:e0213405. [PMID: 30845167 DOI: 10.1371/journal.pone.0213405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014;44:22-30. [PMID: 23701387 DOI: 10.1111/hepr.12166] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
13 Lu C, Fang S, Weng Q, Lv X, Meng M, Zhu J, Zheng L, Hu Y, Gao Y, Wu X, Mao J, Tang B, Zhao Z, Huang L, Ji J. Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma. Cell Commun Signal 2020;18:97. [PMID: 32576292 DOI: 10.1186/s12964-020-00539-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
14 Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014;44:E11-E25. [PMID: 23834468 DOI: 10.1111/hepr.12201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
15 Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, Basta G, Gastaldelli A, Del Ry S. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up. Cytokine 2017;99:59-65. [PMID: 28711012 DOI: 10.1016/j.cyto.2017.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
16 Ingale Y, Routray S, Kheur SM, Kheur M, Mohanty N. Evaluating the efficacy of osteopontin expression as a prognostic marker in oral squamous cell carcinoma in the Indian subpopulation. J Oral Maxillofac Pathol 2014;18:S11-5. [PMID: 25364158 DOI: 10.4103/0973-029X.141327] [Reference Citation Analysis]
17 Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204. [PMID: 23533994 DOI: 10.1155/2013/187204] [Cited by in Crossref: 209] [Cited by in F6Publishing: 201] [Article Influence: 23.2] [Reference Citation Analysis]
18 Rittling SR. Osteopontin in macrophage function. Expert Rev Mol Med 2011;13:e15. [PMID: 21545755 DOI: 10.1017/S1462399411001839] [Cited by in Crossref: 67] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
19 Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer. 2015;4:126-136. [PMID: 26020034 DOI: 10.1159/000367735] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
20 Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One. 2016;11:e0151069. [PMID: 26986465 DOI: 10.1371/journal.pone.0151069] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
21 Imano M, Satou T, Itoh T, Takeyama Y, Yasuda A, Peng Y, Shinkai M, Haji S, Yasuda C, Nakai T, Yasuda T, Imamoto H, Okuno K, Shiozaki H, Ohyanagi H. An Immunohistochemical Study of Osteopontin in Pigment Gallstone Formation. The American Surgeon 2010;76:91-5. [DOI: 10.1177/000313481007600118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hodeib H, ELshora O, Selim A, Sabry NM, El-Ashry HM. Serum Midkine and Osteopontin Levels as Diagnostic Biomarkers of Hepatocellular Carcinoma. Electron Physician 2017;9:3492-8. [PMID: 28243398 DOI: 10.19082/3492] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
23 Hammar SP, Henderson DW, Klebe S, Dodson RF. Neoplasms of the Pleura. In: Tomashefski JF, Cagle PT, Farver CF, Fraire AE, editors. Dail and Hammar’s Pulmonary Pathology. New York: Springer; 2008. pp. 558-734. [DOI: 10.1007/978-0-387-72114-9_12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
24 Sun T, Tang Y, Sun D, Bu Q, Li P. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2018;11:8925-35. [PMID: 30573979 DOI: 10.2147/OTT.S186230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
25 Salem M, Atti SA, Raziky ME, Darweesh SK, Sharkawy ME. Clinical Significance of Plasma Osteopontin Level as a Biomarker of Hepatocellular Carcinoma. Gastroenterology Res 2013;6:191-9. [PMID: 27785253 DOI: 10.4021/gr499w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
26 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2010;4:396-405. [PMID: 20305756 DOI: 10.1007/s12072-009-9157-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
28 Huang H, Zhang XF, Zhou HJ, Xue YH, Dong QZ, Ye QH, Qin LX. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010;101:1314-1319. [PMID: 20345480 DOI: 10.1111/j.1349-7006.2010.01524.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
29 Huang F, Cai P, Wang Y, Zhou X, Chen H, Liao W, Mao Y, Zha X, Zhang H, Hu Z. Up-regulation of brain-expressed X-linked 2 is critical for hepatitis B virus X protein-induced hepatocellular carcinoma development. Oncotarget 2017;8:65789-99. [PMID: 29029472 DOI: 10.18632/oncotarget.19477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, Wu GH, Luk JM. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012; 18(30): 3923-3930 [PMID: 22912540 DOI: 10.3748/wjg.v18.i30.3923] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
31 Bhattacharya SD, Mi Z, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann Surg. 2012;255:319-325. [PMID: 22241292 DOI: 10.1097/SLA.0b013e31823e3a1c] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
32 Honsawek S, Vejchapipat P, Chongsrisawat V, Thawornsuk N, Poovorawan Y. Association of circulating osteopontin levels with clinical outcomes in postoperative biliary atresia. Pediatr Surg Int 2011;27:283-8. [PMID: 21046114 DOI: 10.1007/s00383-010-2799-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
33 Desert R, Ge X, Song Z, Han H, Lantvit D, Chen W, Das S, Athavale D, Abraham-Enachescu I, Blajszczak C, Chen Y, Musso O, Guzman G, Hoshida Y, Nieto N. Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis. Hepatol Commun 2021. [PMID: 34730871 DOI: 10.1002/hep4.1845] [Reference Citation Analysis]
34 Qin L. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med. 2014;8:24-32. [PMID: 24464486 DOI: 10.1007/s11684-014-0312-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
35 Black AP, Mehta AS. The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome. Curr Opin Pharmacol. 2018;41:74-78. [PMID: 29772420 DOI: 10.1016/j.coph.2018.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
36 Kim BS, Joo SH, Lim SJ, Joo KR. Osteopontin Expression in Patients with Hepatolith. Indian J Surg 2015;77:551-6. [PMID: 26730063 DOI: 10.1007/s12262-013-0919-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME. Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis. Am J Gastroenterology 2007;102:2196-205. [DOI: 10.1111/j.1572-0241.2007.01405.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 6.2] [Reference Citation Analysis]
38 Osna NA, Ganesan M, Seth D, Wyatt TA, Kidambi S, Kharbanda KK. Second hits exacerbate alcohol-related organ damage: an update. Alcohol Alcohol 2021;56:8-16. [PMID: 32869059 DOI: 10.1093/alcalc/agaa085] [Reference Citation Analysis]
39 Klebe S, Henderson DW. Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res 2011;189:169-93. [PMID: 21479901 DOI: 10.1007/978-3-642-10862-4_10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
40 Lozada ME, Chaiteerakij R, Roberts LR. Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep 2015;14:128-38. [PMID: 26328266 DOI: 10.1007/s11901-015-0261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
41 Kaps L, Schuppan D. Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells 2020;9:E2027. [PMID: 32899119 DOI: 10.3390/cells9092027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
42 El-din Bessa SS, Elwan NM, Suliman GAM, El-shourbagy SH. Clinical Significance of Plasma Osteopontin Level in Egyptian Patients with Hepatitis C Virus-related Hepatocellular Carcinoma. Archives of Medical Research 2010;41:541-7. [DOI: 10.1016/j.arcmed.2010.10.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
43 Khalil A, Elgedawy J, Faramawi MF, Elfert A, Salama I, Abbass A, Elsaid H, Elsebaai H. Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions. Tumori 2013;99:100-7. [DOI: 10.1177/030089161309900117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
44 Ronald J, Nixon AB, Marin D, Gupta RT, Janas G, Chen W, Suhocki PV, Pabon-Ramos W, Sopko DR, Starr MD, Brady JC, Hurwitz HI, Kim CY. Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. Radiology 2017;285:311-8. [PMID: 28787261 DOI: 10.1148/radiol.2017162555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
45 Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P, Cantaluppi V, Dianzani U, Aspesi A, Chiocchetti A. Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediators Inflamm 2017;2017:4049098. [PMID: 28769537 DOI: 10.1155/2017/4049098] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 17.8] [Reference Citation Analysis]
46 Nakai A, Imano M, Takeyama Y, Shiozaki H, Ohyanagi H. An immunohistochemical study of osteopontin in hepatolithiasis. J Hepatobiliary Pancreat Surg 2008;15:615-21. [PMID: 18987932 DOI: 10.1007/s00534-007-1320-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
47 Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, Liaw L. Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer 2008;8:38. [PMID: 18237408 DOI: 10.1186/1471-2407-8-38] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
48 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 6.5] [Reference Citation Analysis]
49 Wen Y, Jeong S, Xia Q, Kong X. Role of Osteopontin in Liver Diseases. Int J Biol Sci 2016;12:1121-8. [PMID: 27570486 DOI: 10.7150/ijbs.16445] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
50 West CA, Black AP, Mehta AS. Analysis of Hepatocellular Carcinoma Tissue for Biomarker Discovery. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 93-107. [DOI: 10.1007/978-3-030-21540-8_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
51 Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR, Janssen KP. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer. 2007;121:1717-1723. [PMID: 17565744 DOI: 10.1002/ijc.22868] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
52 Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806-14. [PMID: 24247813 DOI: 10.1097/MCG.0000000000000018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
53 Abu El Makarem MA, Abdel-aleem A, Ali A, Saber R, Shatat M, Rahem DA, Sayed D. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Annals of Hepatology 2011;10:296-305. [DOI: 10.1016/s1665-2681(19)31541-8] [Cited by in Crossref: 40] [Article Influence: 4.0] [Reference Citation Analysis]
54 Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med 2015;7:1-10. [PMID: 25926760 DOI: 10.2147/HMER.S50161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
55 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 11.4] [Reference Citation Analysis]
56 Briones-Orta MA, Delgado-Coello B, Gutiérrez-Vidal R, Sosa-Garrocho M, Macías-Silva M, Mas-Oliva J. Quantitative Expression of Key Cancer Markers in the AS-30D Hepatocarcinoma Model. Front Oncol 2021;11:670292. [PMID: 34737944 DOI: 10.3389/fonc.2021.670292] [Reference Citation Analysis]
57 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 13.8] [Reference Citation Analysis]
58 袁运生, 谢旻旗, 钱正昊, 张夕原, 严德珺, 俞雁. 骨桥蛋白: 肝脏疾病中的一个重要分子. 世界华人消化杂志 2011; 19(8): 814-819 [DOI: 10.11569/wcjd.v19.i8.814] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, Chen CM, Huang CC. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol 2009;45:798-802. [PMID: 19213594 DOI: 10.1016/j.oraloncology.2008.12.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
60 Vacante F, Senesi P, Montesano A, Paini S, Luzi L, Terruzzi I. Metformin Counteracts HCC Progression and Metastasis Enhancing KLF6/p21 Expression and Downregulating the IGF Axis. Int J Endocrinol 2019;2019:7570146. [PMID: 30774659 DOI: 10.1155/2019/7570146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
61 Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016;11:e0155800. [PMID: 27219517 DOI: 10.1371/journal.pone.0155800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
62 Sieghart W, Wang X, Schmid K, Pinter M, König F, Bodingbauer M, Wrba F, Rasoul-Rockenschaub S, Peck-Radosavljevic M. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol. 2011;54:89-97. [PMID: 20970216 DOI: 10.1016/j.jhep.2010.06.030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
63 Cao L, Fan X, Jing W, Liang Y, Chen R, Liu Y, Zhu M, Jia R, Wang H, Zhang X, Zhang Y, Zhou X, Zhao J, Guo Y. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway. Oncotarget 2015;6:6627-40. [PMID: 25749383 DOI: 10.18632/oncotarget.3113] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 8.4] [Reference Citation Analysis]
64 Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33. [PMID: 19072390 DOI: 10.1586/17474124.2.3.425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
65 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
66 Chen BL, Zhang GY, Yuan WJ, Wang SP, Shen YM, Yan L, Gu H, Li J. Osteopontin expression is associated with hepatopathologic changes in Schistosoma japonicum infected mice. World J Gastroenterol 2011; 17(46): 5075-5082 [PMID: 22171141 DOI: 10.3748/wjg.v17.i46.5075] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
67 Wan HG, Xu H, Gu YM, Wang H, Xu W, Zu MH. Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res Hepatol Gastroenterol. 2014;38:706-714. [PMID: 25034355 DOI: 10.1016/j.clinre.2014.06.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
68 Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14:2037-2044. [PMID: 20597997 DOI: 10.1111/j.1582-4934.2010.01115.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 10.5] [Reference Citation Analysis]
69 Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma. Hepat Mon 2015;15:e30753. [PMID: 26500684 DOI: 10.5812/hepatmon.30753] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
70 Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259-1266. [PMID: 18699979 DOI: 10.1111/j.1440-1746.2008.05487.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
71 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
72 Li J, Chen X, Dai M, Huang S, Chen J, Dai S. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:543-53. [PMID: 28291627 DOI: 10.1016/j.clinre.2017.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
73 Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab J Gastroenterol. 2014;15:103-107. [PMID: 25249230 DOI: 10.1016/j.ajg.2014.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
74 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 120] [Article Influence: 13.3] [Reference Citation Analysis]
75 Zhang R, Zhang Z, Pan X, Huang X, Huang Z, Zhang G. ATX-LPA Axis Induces Expression of OPN in Hepatic Cancer Cell SMMC7721. Anat Rec 2011;294:406-11. [DOI: 10.1002/ar.21324] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
76 Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, Wu B, Dai Z, Liu YK, Tang ZY. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist. 2008;13:1155-1165. [PMID: 18997126 DOI: 10.1634/theoncologist.2008-0081] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
77 Honsawek S, Chayanupatkul M, Chongsrisawat V, Vejchapipat P, Poovorawan Y. Increased osteopontin and liver stiffness measurement by transient elastography in biliary atresia. World J Gastroenterol 2010; 16(43): 5467-5473 [PMID: 21086566 DOI: 10.3748/wjg.v16.i43.5467] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
78 Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 2008;103:4-13. [PMID: 17890765 DOI: 10.1093/toxsci/kfm246] [Cited by in Crossref: 119] [Cited by in F6Publishing: 109] [Article Influence: 8.5] [Reference Citation Analysis]
79 da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T, Mendy M, Lesi OA. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer. 2015;136:172-181. [PMID: 24803312 DOI: 10.1002/ijc.28953] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
80 Wu JC, Sun BS, Ren N, Ye QH, Qin LX. Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. J Cancer Res Clin Oncol. 2010;136:595-601. [PMID: 19834740 DOI: 10.1007/s00432-009-0695-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
81 Bruha R, Vitek L, Smid V. Osteopontin - A potential biomarker of advanced liver disease. Ann Hepatol 2020;19:344-52. [PMID: 32005637 DOI: 10.1016/j.aohep.2020.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
82 Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843-853. [PMID: 25260312 DOI: 10.1016/j.bpg.2014.07.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
83 Villanueva F, Araya H, Briceño P, Varela N, Stevenson A, Jerez S, Tempio F, Chnaiderman J, Perez C, Villarroel M, Concha E, Khani F, Thaler R, Salazar-Onfray F, Stein GS, van Wijnen AJ, Galindo M. The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis. J Cell Physiol 2019;234:13659-79. [PMID: 30637720 DOI: 10.1002/jcp.28046] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
84 Abdel-Hafiz SM, Hamdy HE, Khorshed FM, Aboushousha TS, Safwat G, Saber MA, Seleem M, Soliman AH. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis. Asian Pac J Cancer Prev 2018;19:1021-7. [PMID: 29693976 DOI: 10.22034/APJCP.2018.19.4.1021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012;130:2685-92. [PMID: 21780114 DOI: 10.1002/ijc.26301] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
86 Honsawek S, Tanavalee A, Sakdinakiattikoon M, Chayanupatkul M, Yuktanandana P. Correlation of plasma and synovial fluid osteopontin with disease severity in knee osteoarthritis. Clin Biochem 2009;42:808-12. [PMID: 19217889 DOI: 10.1016/j.clinbiochem.2009.02.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
87 Seth D, D’souza El-guindy NB, Apte M, Mari M, Dooley S, Neuman M, Haber PS, Kundu GC, Darwanto A, de Villiers WJ, Vonlaufen A, Xu Z, Phillips P, Yang S, Goldstein D, Pirola RM, Wilson JS, Moles A, Fernã¡ndez A, Colell A, Garcã­a-ruiz C, Fernã¡ndez-checa JC, Meyer C, Meindl-beinker NM. Alcohol, Signaling, and ECM Turnover. Alcoholism: Clinical and Experimental Research 2010;34:4-18. [DOI: 10.1111/j.1530-0277.2009.01060.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
88 Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One. 2013;8:e59459. [PMID: 23527199 DOI: 10.1371/journal.pone.0059459] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
89 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
90 Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, Eguchi S, Gu J, Ma D. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis 2018;9:356. [PMID: 29500465 DOI: 10.1038/s41419-018-0391-6] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 31.3] [Reference Citation Analysis]
91 Powers TW, Holst S, Wuhrer M, Mehta AS, Drake RR. Two-Dimensional N-Glycan Distribution Mapping of Hepatocellular Carcinoma Tissues by MALDI-Imaging Mass Spectrometry. Biomolecules 2015;5:2554-72. [PMID: 26501333 DOI: 10.3390/biom5042554] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]